OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.250
-0.020 (-1.57%)
At close: Oct 22, 2026, 4:00 PM EDT
1.250
0.00 (0.00%)
After-hours: Oct 22, 2026, 4:25 PM EDT
OS Therapies Employees
As of December 31, 2025, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes OS Therapies the 41,841st largest employer in the world and 6,495th in the United States.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,873,916
Market Cap
57.76M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - | 4 | 1 |
| Dec 31, 2024 | 5 | 1 | 25.00% | 4 | 1 |
| Mar 31, 2024 | 4 | 0 | - | 3 | 1 |
| Sep 30, 2023 | 4 | 0 | - | 3 | 1 |
| Mar 31, 2023 | 4 | - | - | 3 | 1 |
| Dec 31, 2022 | 4 | - | - | 3 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Caribou Biosciences | 97 |
| Alps Group | 93 |
| XBiotech | 87 |
| MindWalk Holdings | 77 |
| Xilio Therapeutics | 76 |
| Verrica Pharmaceuticals | 76 |
| Pliant Therapeutics | 49 |
OSTX News
- 3 days ago - OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million - Newsfile Corp
- 14 days ago - Rubenstein Public Relations Named Agency of Record for OS Therapies - GlobeNewsWire
- 15 days ago - OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma - Newsfile Corp
- 16 days ago - OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial - Newsfile Corp
- 21 days ago - OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer - Newsfile Corp
- 4 weeks ago - OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) - Newsfile Corp
- 4 weeks ago - OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis - Newsfile Corp
- 5 weeks ago - OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program - Newsfile Corp